tetano
Editor, Senior Moderator
Immunol Invest
. 2021 Apr 30;1-37.
doi: 10.1080/08820139.2021.1904977. Online ahead of print.
Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines
Kirk Hofman[SUP] 1 [/SUP], Gautam N Shenoy[SUP] 2 [/SUP], Vincent Chak[SUP] 1 [/SUP], Sathy V Balu-Iyer[SUP] 1 [/SUP]
Affiliations
Abstract
COVID-19, the disease caused by the novel severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), was first detected in December 2019 and has since morphed into a global pandemic claiming over 2.4 million human lives and severely impacting global economy. The race for a safe and efficacious vaccine was thus initiated with government agencies as well as major pharmaceutical companies as frontrunners. An ideal vaccine would activate multiple arms of the adaptive immune system to generate cytotoxic T cell responses as well as neutralizing antibody responses, while avoiding pathological or deleterious immune responses that result in tissue damage or exacerbation of the disease. Developing an effective vaccine requires an inter-disciplinary effort involving virology, protein biology, biotechnology, immunology and pharmaceutical sciences. In this review, we provide a brief overview of the pathology and immune responses to SARS-CoV-2, which are fundamental to vaccine development. We then summarize the rationale for developing COVID-19 vaccines and provide novel insights into vaccine development from a pharmaceutical science perspective, such as selection of different antigens, adjuvants, delivery platforms and formulations. Finally, we review multiple clinical trial outcomes of novel vaccines in terms of safety and efficacy.
Keywords: COVID-19; SARS-CoV-2; clinical trial; formulation; vaccine.
. 2021 Apr 30;1-37.
doi: 10.1080/08820139.2021.1904977. Online ahead of print.
Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines
Kirk Hofman[SUP] 1 [/SUP], Gautam N Shenoy[SUP] 2 [/SUP], Vincent Chak[SUP] 1 [/SUP], Sathy V Balu-Iyer[SUP] 1 [/SUP]
Affiliations
- PMID: 33929280
- DOI: 10.1080/08820139.2021.1904977
Abstract
COVID-19, the disease caused by the novel severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), was first detected in December 2019 and has since morphed into a global pandemic claiming over 2.4 million human lives and severely impacting global economy. The race for a safe and efficacious vaccine was thus initiated with government agencies as well as major pharmaceutical companies as frontrunners. An ideal vaccine would activate multiple arms of the adaptive immune system to generate cytotoxic T cell responses as well as neutralizing antibody responses, while avoiding pathological or deleterious immune responses that result in tissue damage or exacerbation of the disease. Developing an effective vaccine requires an inter-disciplinary effort involving virology, protein biology, biotechnology, immunology and pharmaceutical sciences. In this review, we provide a brief overview of the pathology and immune responses to SARS-CoV-2, which are fundamental to vaccine development. We then summarize the rationale for developing COVID-19 vaccines and provide novel insights into vaccine development from a pharmaceutical science perspective, such as selection of different antigens, adjuvants, delivery platforms and formulations. Finally, we review multiple clinical trial outcomes of novel vaccines in terms of safety and efficacy.
Keywords: COVID-19; SARS-CoV-2; clinical trial; formulation; vaccine.